New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing ...
Moderna has received the Food and Drug Administration’s approval for RESVIA (mRNA-1345), an mRNA respiratory syncytial virus ...
Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for their ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of GSK's respiratory ...
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 ...
Less than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall, the Food and Drug ...
WASHINGTON, DC - The Biden administration is seeking to delay until at least 2026 the release of COVID-19 vaccine safety data ...
For the first time, an RSV vaccine has been approved for use in adults in their fifties. GSK's Arexy appears to have similar ...
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased ...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.